| General Information | |
|---|---|
| ZINC ID | ZINC000040881021 |
| Molecular Weight (Da) | 498 |
| SMILES | CC(C)(C)c1nc2nc(-c3ccccc3Cl)c(-c3ccc(C(F)(F)F)cc3)cc2c2n[nH]c(=O)n12 |
| Molecular Formula | C25Cl1F3N5O1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 126.46 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 35 |
| LogP | 7.562 |
| Activity (Ki) in nM | 9120.108 |
| Polar Surface Area (PSA) | 76.46 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.009 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 25 |
| Fraction csp3 | 0.2 |
| Ilogp | 3.73 |
| Xlogp3 | 5.99 |
| Wlogp | 7.42 |
| Mlogp | 5.23 |
| Silicos-it log p | 6.45 |
| Consensus log p | 5.77 |
| Esol log s | -6.97 |
| Esol solubility (mg/ml) | 0.0000539 |
| Esol solubility (mol/l) | 0.0000001 |
| Esol class | Poorly sol |
| Ali log s | -7.36 |
| Ali solubility (mg/ml) | 0.0000216 |
| Ali solubility (mol/l) | 4.35E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.12 |
| Silicos-it solubility (mg/ml) | 3.76E-08 |
| Silicos-it solubility (mol/l) | 7.55E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.08 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.5 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.679 |
| Logd | 4.927 |
| Logp | 6.296 |
| F (20%) | 0.086 |
| F (30%) | 0.139 |
| Mdck | 1.35E-05 |
| Ppb | 0.9988 |
| Vdss | 0.94 |
| Fu | 0.0083 |
| Cyp1a2-inh | 0.664 |
| Cyp1a2-sub | 0.657 |
| Cyp2c19-inh | 0.871 |
| Cyp2c19-sub | 0.062 |
| Cl | 4.579 |
| T12 | 0.08 |
| H-ht | 0.897 |
| Dili | 0.969 |
| Roa | 0.026 |
| Fdamdd | 0.896 |
| Skinsen | 0.037 |
| Ec | 0.003 |
| Ei | 0.011 |
| Respiratory | 0.23 |
| Bcf | 2.244 |
| Igc50 | 4.993 |
| Lc50 | 6.664 |
| Lc50dm | 6.916 |
| Nr-ar | 0.01 |
| Nr-ar-lbd | 0.497 |
| Nr-ahr | 0.371 |
| Nr-aromatase | 0.896 |
| Nr-er | 0.6 |
| Nr-er-lbd | 0.825 |
| Nr-ppar-gamma | 0.976 |
| Sr-are | 0.908 |
| Sr-atad5 | 0.008 |
| Sr-hse | 0.237 |
| Sr-mmp | 0.927 |
| Sr-p53 | 0.95 |
| Vol | 463.724 |
| Dense | 1.072 |
| Flex | 0.143 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 2 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 3 |
| Surechembl | 0 |
| Nonbiodegradable | 5 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 3 |
| Toxicophores | 0 |
| Qed | 0.312 |
| Synth | 2.863 |
| Fsp3 | 0.2 |
| Mce-18 | 33 |
| Natural product-likeness | -1.069 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 3 |
| Gsk | Rejected |
| Goldentriangle | Accepted |